Sat, Jul 12, 2014, 5:18 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • carl463681 carl463681 Aug 29, 2010 9:50 AM Flag

    O.T. "XOMAD" Potential Takeover Target By SNY or GSK


    XOMA's 052 Designated Orphan Drug by FDA

    Xoma Presenting at the Rodman & Renshaw Annual Global Investment Conference 12th Annual Healthcare Conference September 12-15, 2010 New York, NY

    Listen to XOMA Ltd. Second Quarter 2010 Financial Results Conference Call (8/9/2010) for an overview of the situation:

    "XOMAD should be above $6.00 here."

    "Last week's 1 – 15 reverse split is impacting the share price."

    "Substantially oversold."

    "Current price is equal to about 18 cents pre-split."

    "52 week high was $16.05 on a post split basis. Bottomed at $2.45 on Tuesday."

    "Current market cap is only $64 million. Companies with no track record of product development and a similar drug in the pipeline are valued at many times what XOMA is currently."

    "GSK needs a replacement for Avandia. Potential suitor."

    "SNY has spent over $17 billion on 25 acquisitions over the last two years."

    "Company is currently self-funded through the next 12 months with almost $100,000,000 in revenues."

    "Buy it before the gap-up."

    "Partnership announcement takes it above $20.00."

    "Due diligence but do buy a few shares here."

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
51.63-0.04(-0.08%)Jul 11 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.